The DOI matches its Crossref record; 176 of the 176 references it cites were found in a registry or an index.
Current approaches of nanomedicines in the market and various stage of clinical translation
Open accessAbstract
Compared with traditional drug therapy, nanomedicines exhibit intriguing biological features to increase therapeutic efficiency, reduce toxicity and achieve targeting delivery. This review provides a snapshot of nanomedicines that have been currently launched or in the clinical trials, which manifests a diversified trend in carrier types, applied indications and mechanisms of action. From the perspective of indications, this article presents an overview of the applications of nanomedicines involving the prevention, diagnosis and treatment of various diseases, which include cancer, infections, blood disorders, cardiovascular diseases, immuno-associated diseases and nervous system diseases, etc. Moreover, the review provides some considerations and perspectives in the research and development of nanomedicines to facilitate their translations in clinic.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cancer nanomedicine: progress, challenges and opportunities
Shi, J., Kantoff, P. W., Wooster, R., & Farokhzad, O. C. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.108 · Cited by 5,873
Doxil® — The first FDA-approved nano-drug: Lessons learned
Barenholz, Y. (. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.03.020 · Cited by 4,792
mRNA vaccines — a new era in vaccinology
Pardi, N., Hogan, M. J., Porter, F. W., & Weissman, D. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.243 · Cited by 4,667
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
Adams, D., Gonzalez-Duarte, A., O’Riordan, W. D., Yang, C.-C., Ueda, M., Kristen, A. V., Tournev, I., Schmidt, H. H., Coelho, T., Berk, J. L., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716153 · Cited by 3,047
Extracellular vesicles as a next-generation drug delivery platform
Herrmann, I. K., Wood, M. J. A., & Fuhrmann, G. (2021) · Nature Nanotechnology · doi:10.1038/s41565-021-00931-2 · Cited by 1,948
CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis
Gillmore, J. D., Gane, E., Taubel, J., Kao, J., Fontana, M., Maitland, M. L., Seitzer, J., O’Connell, D., Walsh, K. R., Wood, K., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107454 · Cited by 1,801
Nanoparticles in the clinic: an update
Anselmo, A. C., & Mitragotri, S. (2019) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10143 · Cited by 1,766
The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs
Akinc, A., Maier, M. A., Manoharan, M., Fitzgerald, K., Jayaraman, M., Barros, S., Ansell, S., Du, X., Hope, M. J., Madden, T. D., et al. (2019) · Nature Nanotechnology · doi:10.1038/s41565-019-0591-y · Cited by 1,636
Saxena, M., van der Burg, S. H., Melief, C. J. M., & Bhardwaj, N. (2021) · Nature reviews. Cancer · doi:10.1038/s41568-021-00346-0 · Cited by 1,581
Albumin-based nanoparticles as potential controlled release drug delivery systems
Elzoghby, A. O., Samy, W. M., & Elgindy, N. A. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.07.031 · Cited by 1,520
Block copolymer micelles in nanomedicine applications
Cabral, H., Miyata, K., Osada, K., & Kataoka, K. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00199 · Cited by 1,309
Tumor targeting via EPR: Strategies to enhance patient responses
Golombek, S. K., May, J.-N., Theek, B., Appold, L., Drude, N., Kiessling, F., & Lammers, T. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.07.007 · Cited by 1,262
van der Meel, R., Sulheim, E., Shi, Y., Kiessling, F., Mulder, W. J. M., & Lammers, T. (2019) · Nature Nanotechnology · doi:10.1038/s41565-019-0567-y · Cited by 1,234
Challenges and strategies in anti-cancer nanomedicine development: An industry perspective
Hare, J. I., Lammers, T., Ashford, M. B., Puri, S., Storm, G., & Barry, S. T. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.04.025 · Cited by 1,214
Extracellular vesicles as drug delivery systems: Why and how?
Elsharkasy, O. M., Nordin, J. Z., Hagey, D. W., de Jong, O. G., Schiffelers, R. M., Andaloussi, S. E., & Vader, P. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.04.004 · Cited by 1,197
Targeted drug delivery strategies for precision medicines
Manzari, M. T., Shamay, Y., Kiguchi, H., Rosen, N., Scaltriti, M., & Heller, D. A. (2021) · Nature Reviews Materials · doi:10.1038/s41578-020-00269-6 · Cited by 1,183
Melief, C. J. M., van Hall, T., Arens, R., Ossendorp, F., & van der Burg, S. H. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80009 · Cited by 1,164
Davis, M. E. (2009) · Molecular Pharmaceutics · doi:10.1021/mp900015y · Cited by 977
Exosome-based liquid biopsies in cancer: opportunities and challenges
Yu, W., Hurley, J., Roberts, D., Chakrabortty, S. K., Enderle, D., Noerholm, M., Breakefield, X. O., & Skog, J. K. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.01.074 · Cited by 870
Enzyme-activatable polymer–drug conjugate augments tumour penetration and treatment efficacy
Zhou, Q., Shao, S., Wang, J., Xu, C., Xiang, J., Piao, Y., Zhou, Z., Yu, Q., Tang, J., Liu, X., et al. (2019) · Nature Nanotechnology · doi:10.1038/s41565-019-0485-z · Cited by 819
Antibody–drug conjugates for cancer
Chau, C. H., Steeg, P. S., & Figg, W. D. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31774-x · Cited by 816
Transport of drugs from blood vessels to tumour tissue
Dewhirst, M. W., & Secomb, T. W. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.93 · Cited by 749
Liposomes: Advancements and innovation in the manufacturing process
Shah, S., Dhawan, V., Holm, R., Nagarsenker, M. S., & Perrie, Y. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.07.002 · Cited by 745
Clinical translation of an ultrasmall inorganic optical-PET imaging nanoparticle probe
Phillips, E., Penate-Medina, O., Zanzonico, P. B., Carvajal, R. D., Mohan, P., Ye, Y., Humm, J., Gönen, M., Kalaigian, H., Schöder, H., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3009524 · Cited by 712
Kozma, G. T., Shimizu, T., Ishida, T., & Szebeni, J. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.07.024 · Cited by 696
Turning the corner on therapeutic cancer vaccines
Hollingsworth, R. E., & Jansen, K. (2019) · npj Vaccines · doi:10.1038/s41541-019-0103-y · Cited by 689
Nanopharmaceuticals and Nanomedicines Currently on the Market: Challenges and Opportunities
Farjadian, F., Ghasemi, A., Gohari, O., Roointan, A., Karimi, M., & Hamblin, M. R. (2019) · Nanomedicine · doi:10.2217/nnm-2018-0120 · Cited by 664
Reimer, P., & Balzer, T. (2003) · European Radiology · doi:10.1007/s00330-002-1721-7 · Cited by 614
Harnessing albumin as a carrier for cancer therapies
Hoogenboezem, E. N., & Duvall, C. L. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.07.011 · Cited by 610
Peptide-based synthetic vaccines
Skwarczynski, M., & Toth, I. (2016) · Chemical Science · doi:10.1039/c5sc03892h · Cited by 596
Radioimmunotherapy of human tumours
Larson, S. M., Carrasquillo, J. A., Cheung, N.-K. V., & Press, O. W. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3925 · Cited by 537
Bonvalot, S., Rutkowski, P. L., Thariat, J., Carrère, S., Ducassou, A., Sunyach, M.-P., Agoston, P., Hong, A., Mervoyer, A., Rastrelli, M., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30326-2 · Cited by 536
Walls, A. C., Fiala, B., Schäfer, A., Wrenn, S., Pham, M. N., Murphy, M., Tse, L. V., Shehata, L., O’Connor, M. A., Chen, C., et al. (2020) · Cell · doi:10.1016/j.cell.2020.10.043 · Cited by 532
Thi, T. T. H., Suys, E. J. A., Lee, J. S., Nguyen, D. H., Park, K. D., & Truong, N. P. (2021) · Vaccines · doi:10.3390/vaccines9040359 · Cited by 525
A framework for designing delivery systems
Poon, W., Kingston, B. R., Ouyang, B., Ngo, W., & Chan, W. C. W. (2020) · Nature Nanotechnology · doi:10.1038/s41565-020-0759-5 · Cited by 524
Integrating Artificial Intelligence and Nanotechnology for Precision Cancer Medicine
Adir, O., Poley, M., Chen, G., Froim, S., Krinsky, N., Shklover, J., Shainsky‐Roitman, J., Lammers, T., & Schroeder, A. (2020) · Advanced Materials · doi:10.1002/adma.201901989 · Cited by 496
Obstacles and opportunities in a forward vision for cancer nanomedicine
de Lázaro, I., & Mooney, D. J. (2021) · Nature Materials · doi:10.1038/s41563-021-01047-7 · Cited by 439
Wolfram, J., & Ferrari, M. (2019) · Nano Today · doi:10.1016/j.nantod.2019.02.005 · Cited by 436
Zuckerman, J. E., Gritli, I., Tolcher, A., Heidel, J. D., Lim, D., Morgan, R., Chmielowski, B., Ribas, A., Davis, M. E., & Yen, Y. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1411393111 · Cited by 427
Engineered T Cell Therapy for Cancer in the Clinic
Zhao, L., & Cao, Y. J. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02250 · Cited by 410
Sustainable technologies for liposome preparation
Maja, L., Željko, K., & Mateja, P. (2020) · The Journal of Supercritical Fluids · doi:10.1016/j.supflu.2020.104984 · Cited by 398
Cancer DNA vaccines: current preclinical and clinical developments and future perspectives
Lopes, A., Vandermeulen, G., & Préat, V. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1154-7 · Cited by 385
COVID-19 vaccines: The status and perspectives in delivery points of view
Chung, J. Y., Thone, M. N., & Kwon, Y. J. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.12.011 · Cited by 375
Lamb, Y. N. (2021) · Drugs · doi:10.1007/s40265-021-01473-6 · Cited by 359
Extracellular vesicles versus synthetic nanoparticles for drug delivery
Witwer, K. W., & Wolfram, J. (2021) · Nature Reviews Materials · doi:10.1038/s41578-020-00277-6 · Cited by 337
Adjuvanting a subunit COVID-19 vaccine to induce protective immunity
Arunachalam, P. S., Walls, A. C., Golden, N., Atyeo, C., Fischinger, S., Li, C., Aye, P., Navarro, M. J., Lai, L., Edara, V. V., et al. (2021) · Nature · doi:10.1038/s41586-021-03530-2 · Cited by 326
Talimogene Laherparepvec (T-VEC) and Other Oncolytic Viruses for the Treatment of Melanoma
Bommareddy, P. K., Patel, A., Hossain, S., & Kaufman, H. L. (2017) · American Journal of Clinical Dermatology · doi:10.1007/s40257-016-0238-9 · Cited by 322
Kitai, Y., Kawasaki, T., Sueyoshi, T., Kobiyama, K., Ishii, K. J., Zou, J., Akira, S., Matsuda, T., & Kawai, T. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1601694 · Cited by 318
The First Approved Gene Therapy Product for Cancer Ad- p53 (Gendicine): 12 Years in the Clinic
Zhang, W.-W., Li, L., Li, D., Liu, J., Li, X., Li, W., Xu, X., Zhang, M. J., Chandler, L. A., Lin, H., et al. (2018) · Human Gene Therapy · doi:10.1089/hum.2017.218 · Cited by 318
Progress, challenges, and future of nanomedicine
Zhang, C., Yan, L., Wang, X., Zhu, S., Chen, C., Gu, Z., & Zhao, Y. (2020) · Nano Today · doi:10.1016/j.nantod.2020.101008 · Cited by 318
Oncorine, the World First Oncolytic Virus Medicine and its Update in China
Liang, M. (2018) · Current Cancer Drug Targets · doi:10.2174/1568009618666171129221503 · Cited by 314
Lim, J.-M., Swami, A., Gilson, L. M., Chopra, S., Choi, S., Wu, J., Langer, R., Karnik, R., & Farokhzad, O. C. (2014) · ACS Nano · doi:10.1021/nn501371n · Cited by 297
Inducing immune tolerance with dendritic cell-targeting nanomedicines
Cifuentes-Rius, A., Desai, A., Yuen, D., Johnston, A. P. R., & Voelcker, N. H. (2021) · Nature Nanotechnology · doi:10.1038/s41565-020-00810-2 · Cited by 297
Bioengineering bacterial outer membrane vesicles as vaccine platform
Gerritzen, M. J. H., Martens, D. E., Wijffels, R. H., van der Pol, L., & Stork, M. (2017) · Biotechnology Advances · doi:10.1016/j.biotechadv.2017.05.003 · Cited by 290
Clinical overview on Lipoplatin™: a successful liposomal formulation of cisplatin
Boulikas, T. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780903114168 · Cited by 276
Facilitating the translation of nanomedicines to a clinical product: challenges and opportunities
Agrahari, V., & Agrahari, V. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2018.01.047 · Cited by 253
Imaging‐guided convection‐enhanced delivery and gene therapy of glioblastoma
Voges, J., Reszka, R., Gossmann, A., Dittmar, C., Richter, R., Garlip, G., Kracht, L., Coenen, H. H., Sturm, V., Wienhard, K., et al. (2003) · Annals of Neurology · doi:10.1002/ana.10688 · Cited by 250
Application of quality by design in the current drug development
Zhang, L., & Mao, S. (2017) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2016.07.006 · Cited by 246
Liu, D., Zhang, H., Fontana, F., Hirvonen, J. T., & Santos, H. A. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.08.003 · Cited by 238
Antibody–Drug Conjugates—A Tutorial Review
Baah, S., Laws, M., & Rahman, K. M. (2021) · Molecules · doi:10.3390/molecules26102943 · Cited by 236
Intratumoral IL12 mRNA Therapy Promotes TH1 Transformation of the Tumor Microenvironment
Hewitt, S. L., Bailey, D., Zielinski, J., Apte, A., Musenge, F., Karp, R., Burke, S., Garcon, F., Mishra, A., Gurumurthy, S., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0472 · Cited by 227
Dendrimers in combination with natural products and analogues as anti-cancer agents
Mignani, S., Rodrigues, J., Tomas, H., Zablocka, M., Shi, X., Caminade, A.-M., & Majoral, J.-P. (2018) · Chemical Society Reviews · doi:10.1039/c7cs00550d · Cited by 219
Zhou, Q., Dong, C., Fan, W., Jiang, H., Xiang, J., Qiu, N., Piao, Y., Xie, T., Luo, Y., Li, Z., et al. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.119902 · Cited by 218
Feng, B., Niu, Z., Hou, B., Zhou, L., Li, Y., & Yu, H. (2020) · Advanced Functional Materials · doi:10.1002/adfm.201906605 · Cited by 215
Self-citationAdvanced Nanotechnology Leading the Way to Multimodal Imaging‐Guided Precision Surgical Therapy
Wang, C., Fan, W., Zhang, Z., Wen, Y., Xiong, L., & Chen, X. (2019) · Advanced Materials · doi:10.1002/adma.201904329 · Cited by 213
Self-citationConvection-enhanced delivery in glioblastoma: a review of preclinical and clinical studies
Jahangiri, A., Chin, A. T., Flanigan, P. M., Chen, R., Bankiewicz, K., & Aghi, M. K. (2017) · Journal of Neurosurgery · doi:10.3171/2016.1.jns151591 · Cited by 212
Kelly, C. M., Antonescu, C. R., Bowler, T., Munhoz, R., Chi, P., Dickson, M. A., Gounder, M. M., Keohan, M. L., Movva, S., Dholakia, R., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2019.6152 · Cited by 209
Future of the Particle Replication in Nonwetting Templates (PRINT) Technology
Xu, J., Wong, D. H. C., Byrne, J. D., Chen, K., Bowerman, C., & DeSimone, J. M. (2013) · Angewandte Chemie International Edition · doi:10.1002/anie.201209145 · Cited by 208
Physical Activity and Exercise in Lung Cancer Care: Will Promises Be Fulfilled?
Avancini, A., Sartori, G., Gkountakos, A., Casali, M., Trestini, I., Tregnago, D., Bria, E., Jones, L. W., Milella, M., Lanza, M., et al. (2020) · The Oncologist · doi:10.1634/theoncologist.2019-0463 · Cited by 207
Exosome-based candidates move into the clinic
Cully, M. (2021) · Nature Reviews Drug Discovery · doi:10.1038/d41573-020-00220-y · Cited by 204
Talimogene Laherparepvec (T-VEC) for the Treatment of Advanced Melanoma
Johnson, D. B., Puzanov, I., & Kelley, M. C. (2015) · Immunotherapy · doi:10.2217/imt.15.35 · Cited by 203
The Changing Landscape of Therapeutic Cancer Vaccines—Novel Platforms and Neoantigen Identification
Jou, J., Harrington, K. J., Zocca, M.-B., Ehrnrooth, E., & Cohen, E. E. W. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0245 · Cited by 203
Langer, C. J., O’Byrne, K. J., Socinski, M. A., Mikhailov, S. M., Leśniewski-Kmak, K., Smakal, M., Ciuleanu, T. E., Orlov, S. V., Dediu, M., Heigener, D., et al. (2008) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181753b4b · Cited by 202
Novel Prodrugs of SN38 Using Multiarm Poly(ethylene glycol) Linkers
Zhao, H., Rubio, B., Sapra, P., Wu, D., Reddy, P., Sai, P., Martinez, A., Gao, Y., Lozanguiez, Y., Longley, C., et al. (2008) · Bioconjugate Chemistry · doi:10.1021/bc700333s · Cited by 188
Herman, J. M., Wild, A. T., Wang, H., Tran, P. T., Chang, K. J., Taylor, G. E., Donehower, R. C., Pawlik, T. M., Ziegler, M. A., Cai, H., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.7516 · Cited by 186
Wang, Y., Jiang, Y., Wei, D., Singh, P., Yu, Y., Lee, T., Zhang, L., Mandl, H. K., Piotrowski-Daspit, A. S., Chen, X., et al. (2021) · Nature Biomedical Engineering · doi:10.1038/s41551-021-00728-7 · Cited by 183
Nanomedicines accessible in the market for clinical interventions
Gadekar, V., Borade, Y., Kannaujia, S., Rajpoot, K., Anup, N., Tambe, V., Kalia, K., & Tekade, R. K. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.12.034 · Cited by 182
Active transcytosis and new opportunities for cancer nanomedicine
Pandit, S., Dutta, D., & Nie, S. (2020) · Nature Materials · doi:10.1038/s41563-020-0672-1 · Cited by 181
Voskuil, F. J., Steinkamp, P. J., Zhao, T., van der Vegt, B., Koller, M., Doff, J. J., Jayalakshmi, Y., Hartung, J. P., Gao, J., Sumer, B. D., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16814-4 · Cited by 180
Nanomaterials arising amid antibiotic resistance
Gao, W., & Zhang, L. (2021) · Nature Reviews Microbiology · doi:10.1038/s41579-020-00469-5 · Cited by 179
Wang, D., Li, S., Zhao, Z., Zhang, X., & Tan, W. (2021) · Angewandte Chemie International Edition · doi:10.1002/anie.202103993 · Cited by 177
Triamcinolone Acetonide Extended-Release: A Review in Osteoarthritis Pain of the Knee
Paik, J., Duggan, S. T., & Keam, S. J. (2019) · Drugs · doi:10.1007/s40265-019-01083-3 · Cited by 168
Zhang, Z., Wang, H., Tan, T., Li, J., Wang, Z., & Li, Y. (2018) · Advanced Functional Materials · doi:10.1002/adfm.201801840 · Cited by 165
Self-citationWang, L. L., Janes, M. E., Kumbhojkar, N., Kapate, N., Clegg, J. R., Prakash, S., Heavey, M. K., Zhao, Z., Anselmo, A. C., & Mitragotri, S. (2021) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10214 · Cited by 162
ExoSTING, an extracellular vesicle loaded with STING agonists, promotes tumor immune surveillance
Jang, S. C., Economides, K. D., Moniz, R. J., Sia, C. L., Lewis, N., McCoy, C., Zi, T., Zhang, K., Harrison, R. A., Lim, J., et al. (2021) · Communications Biology · doi:10.1038/s42003-021-02004-5 · Cited by 162
Long Non-Coding RNAs as Master Regulators in Cardiovascular Diseases
Archer, K., Broskova, Z., Bayoumi, A., Teoh, J.-P., Davila, A., Tang, Y., Su, H., & Kim, I.-M. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms161023651 · Cited by 159
Adams, D., Polydefkis, M., González-Duarte, A., Wixner, J., Kristen, A. V., Schmidt, H. H., Berk, J. L., Losada López, I. A., Dispenzieri, A., Quan, D., et al. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30368-9 · Cited by 158
Alnylam launches era of RNAi drugs
Garber, K. (2018) · Nature Biotechnology · doi:10.1038/nbt0918-777 · Cited by 157
Recent advances of bispecific antibodies in solid tumors
Yu, S., Li, A., Liu, Q., Yuan, X., Xu, H., Jiao, D., Pestell, R. G., Han, X., & Wu, K. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0522-z · Cited by 154
Agrahari, V., Agrahari, V., Chou, M., Chew, C. H., Noll, J., & Burnouf, T. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.120163 · Cited by 153
The progress and perspective of nanoparticle-enabled tumor metastasis treatment
Zhang, W., Wang, F., Hu, C., Zhou, Y., Gao, H., & Hu, J. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.07.013 · Cited by 153
The progress and perspective of strategies to improve tumor penetration of nanomedicines
Hu, J., Yuan, X., Wang, F., Gao, H., Liu, X., & Zhang, W. (2020) · Chinese Chemical Letters · doi:10.1016/j.cclet.2020.11.006 · Cited by 144
Albumin nanoscience: homing nanotechnology enabling targeted drug delivery and therapy
Lamichhane, S., & Lee, S. (2020) · Archives of Pharmacal Research · doi:10.1007/s12272-020-01204-7 · Cited by 139
Fang, L., Zhao, Z., Wang, J., Zhang, P., Ding, Y., Jiang, Y., Wang, D., & Li, Y. (2020) · Science Advances · doi:10.1126/sciadv.aba4024 · Cited by 134
Self-citationIssues and concerns in nanotech product development and its commercialization
Kaur, I. P., Kakkar, V., Deol, P. K., Yadav, M., Singh, M., & Sharma, I. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.06.005 · Cited by 132
Mehta, P. P., Ghoshal, D., Pawar, A., Kadam, S. S., & Dhapte-Pawar, V. S. (2020) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2020.101509 · Cited by 132
Nanoparticles-mediated reoxygenation strategy relieves tumor hypoxia for enhanced cancer therapy
Wang, H., Li, J., Wang, Y., Gong, X., Xu, X., Wang, J., Li, Y., Sha, X., & Zhang, Z. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.12.028 · Cited by 129
Self-citationRespirable nanocarriers as a promising strategy for antitubercular drug delivery
Mehanna, M. M., Mohyeldin, S. M., & Elgindy, N. A. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.05.038 · Cited by 122
Peltek, O. O., Muslimov, A. R., Zyuzin, M. V., & Timin, A. S. (2019) · Journal of Nanobiotechnology · doi:10.1186/s12951-019-0524-9 · Cited by 118
Cancer Modeling‐on‐a‐Chip with Future Artificial Intelligence Integration
Fetah, K., DiPardo, B. J., Kongadzem, E.-M. L., Tomlinson, J. S., Elzagheid, A. I., Elmusrati, M. S., Khademhosseini, A., & Ashammakhi, N. A. (2019) · Small · doi:10.1002/smll.201901985 · Cited by 118
Bullivant, J. P., Zhao, S., Willenberg, B. J., Kozissnik, B., Batich, C. D., & Dobson, J. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms140917501 · Cited by 117
Targeted Delivery to Tumors: Multidirectional Strategies to Improve Treatment Efficiency
Kutova, O. M., Guryev, E. L., Соколова, Е. А., Alzeibak, R., & Balalaeva, I. V. (2019) · Cancers · doi:10.3390/cancers11010068 · Cited by 116
Kageyama, S., Wada, H., Muro, K., Niwa, Y., Ueda, S., Miyata, H., Takiguchi, S., Sugino, S. H., Miyahara, Y., Ikeda, H., et al. (2013) · Journal of Translational Medicine · doi:10.1186/1479-5876-11-246 · Cited by 115
Paithankar, D. Y., Sakamoto, F. H., Farinelli, W. A., Kositratna, G., Blomgren, R. D., Meyer, T. J., Faupel, L. J., Kauvar, A. N. B., Lloyd, J. R., Cheung, W. L., et al. (2015) · Journal of Investigative Dermatology · doi:10.1038/jid.2015.89 · Cited by 112
Liposomes for Pulmonary Drug Delivery: The Role of Formulation and Inhalation Device Design
Elhissi, A. M. A. (2017) · Current Pharmaceutical Design · doi:10.2174/1381612823666161116114732 · Cited by 110
Loncastuximab Tesirine: First Approval
Lee, A. (2021) · Drugs · doi:10.1007/s40265-021-01550-w · Cited by 110
Chuang, L. I. U., Luo, L., Zeng, L., Xing, J., Xia, Y., Sun, S., Zhang, L., Yu, Z., Yao, J., Yu, Z., et al. (2018) · Small · doi:10.1002/smll.201801851 · Cited by 109
Emerging antibacterial nanomedicine for enhanced antibiotic therapy
Wang, S., Gao, Y., Jin, Q., & Ji, J. (2020) · Biomaterials Science · doi:10.1039/d0bm00974a · Cited by 108
Wang, Z., Gong, X., Li, J., Wang, H., Xu, X., Li, Y., Sha, X., & Zhang, Z. (2021) · ACS Nano · doi:10.1021/acsnano.1c00033 · Cited by 106
Self-citationAlbumin-based potential drugs: focus on half-life extension and nanoparticle preparation
Lee, E. S., & Youn, Y. S. (2016) · Journal of Pharmaceutical Investigation · doi:10.1007/s40005-016-0250-3 · Cited by 103
Wang, H., Ding, T., Guan, J., Liu, X., Wang, J., Jin, P., Hou, S., Lu, W., Qian, J., Wang, W., et al. (2020) · ACS Nano · doi:10.1021/acsnano.0c02821 · Cited by 103
Smits, M. L. J., Dassen, M. G., Prince, J. F., Braat, A. J. A. T., Beijst, C., Bruijnen, R. C. G., de Jong, H. W. A. M., & Lam, M. G. E. H. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04460-y · Cited by 102
Prados, M. D., McDermott, M., Chang, S. M., Wilson, C. B., Fick, J. R., Culver, K. W., Gilder, J. V., Keles, G. E., Spence, A. M., & Berger, M. S. (2003) · Journal of Neuro-Oncology · doi:10.1023/b:neon.0000003588.18644.9c · Cited by 101
Immunoliposomes in clinical oncology: State of the art and future perspectives
Merino, M., Zalba, S., & Garrido, M. J. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.02.015 · Cited by 101
Variant SARS-CoV-2 mRNA vaccines confer broad neutralization as primary or booster series in mice
(2021) · doi:10.1016/j.vaccine.2021.11.001 · Cited by 101
Implications of nanotechnology for the treatment of cancer: Recent advances
Klochkov, S. G., Неганова, М. Е., Nikolenko, V. N., Chen, K., Somasundaram, S. G., Kirkland, C. E., & Aliev, G. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.08.028 · Cited by 100
Antibody-drug conjugates in clinical trials for lymphoid malignancies and multiple myeloma
Yu, B., & Liu, D. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0786-6 · Cited by 97
Surface chemistry and serum type both determine the nanoparticle–protein corona
Pozzi, D., Caracciolo, G., Capriotti, A. L., Cavaliere, C., Barbera, G. L., Anchordoquy, T. J., & Laganà, A. (2015) · Journal of Proteomics · doi:10.1016/j.jprot.2015.02.009 · Cited by 90
Slingerland, M., Guchelaar, H., Rosing, H., Scheulen, M. E., van Warmerdam, L. J. C., Beijnen, J. H., & Gelderblom, H. A. J. (2013) · Clinical Therapeutics · doi:10.1016/j.clinthera.2013.10.009 · Cited by 89
Solomon, B., Desai, J., Rosenthal, M. A., McArthur, G. A., Pattison, S. T., Pattison, S. L., MacDiarmid, J. A., Brahmbhatt, H. N., & Scott, A. M. (2015) · PLoS ONE · doi:10.1371/journal.pone.0144559 · Cited by 87
Fundamentals, challenges, and nanomedicine‐based solutions for ocular diseases
Srinivasarao, D. A., Lohiya, G., & Katti, D. S. (2018) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1548 · Cited by 87
Zhang, K., Loong, S. L. E., Connor, S., Yu, S. W.-K., Tan, S., Ng, R. T. H., Lee, K. M., Canham, L., & Chow, P. K. H. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0400 · Cited by 81
Hamilton, G. S. (2015) · Biologicals · doi:10.1016/j.biologicals.2015.05.006 · Cited by 79
A Quality by Design Approach to Developing and Manufacturing Polymeric Nanoparticle Drug Products
Troiano, G., Nolan, J., Parsons, D. M., Hoven, C. V. G., & Zale, S. E. (2016) · The AAPS Journal · doi:10.1208/s12248-016-9969-z · Cited by 79
Aspartate β-hydroxylase as a target for cancer therapy
Kanwal, M., Šmahel, M., Olsen, M. J., Šmahelová, J., & Tachezy, R. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01669-w · Cited by 79
Improving the Treatment of Acute Lymphoblastic Leukemia
Radadiya, A., Zhu, W., Coricello, A., Alcaro, S., & Richards, N. G. J. (2020) · Biochemistry · doi:10.1021/acs.biochem.0c00354 · Cited by 75
Delivery routes matter: Safety and efficacy of intratumoral immunotherapy
Lombaerde, E. D., Wever, O. D., & Geest, B. G. D. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188526 · Cited by 73
Johnson, M., El-Khoueiry, A., Hafez, N., Lakhani, N., Mamdani, H., Rodon, J., Sanborn, R. E., Garcia-Corbacho, J., Boni, V., Stroh, M., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0194 · Cited by 72
Li, J., Wang, H., Wang, Y., Gong, X., Xu, X., Sha, X., Zhang, A., Zhang, Z., & Li, Y. (2020) · Advanced Materials · doi:10.1002/adma.202002380 · Cited by 72
Self-citationSchultheis, B. S., Strumberg, D., Kuhlmann, J. B., Wolf, M., Link, K., Seufferlein, T. T. W., Kaufmann, J., Feist, M., Gebhardt, F., Khan, M., et al. (2020) · Cancers · doi:10.3390/cancers12113130 · Cited by 72
Kinoh, H., Quader, S., Shibasaki, H., Liu, X., Maity, A. R., Yamasoba, T., Cabral, H., & Kataoka, K. (2020) · ACS Nano · doi:10.1021/acsnano.0c03386 · Cited by 70
Luan, X., Yuan, H., Song, Y., Hu, H., Wen, B., He, M., Zhang, H., Li, Y., Li, F., Pan, S., et al. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2021.120910 · Cited by 70
Self-citationNanodelivery Systems for Topical Management of Skin Disorders
Cui, M., Wiraja, C., Chew, S. W. T., & Xu, C. (2020) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.0c00154 · Cited by 68
Translational considerations in nanomedicine: The oncology perspective
Gabizón, A., de Rosales, R. T. M., & La-Beck, N. M. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.05.012 · Cited by 64
Powell, J. S., Nugent, D. J., HARRISON, J. A., Soni, A., Luk, A. Y., STASS, H., & Gorina, E. (2008) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2007.02856.x · Cited by 62
Liu, X., Wang, D., Zhang, P., & Li, Y. (2019) · Nano Today · doi:10.1016/j.nantod.2019.100801 · Cited by 62
Self-citationLee, J.-C., Shin, D. W., Park, H., Kim, J., Youn, Y., Kim, J. H., Kim, J., & Hwang, J. (2020) · Gastrointestinal Endoscopy · doi:10.1016/j.gie.2020.02.012 · Cited by 60
Genito, C. J., Beck, Z., Phares, T. W., Kalle, F., Limbach, K. J., Stefaniak, M. E., Patterson, N. B., Bergmann‐Leitner, E. S., Waters, N. C., Matyas, G. R., et al. (2017) · Vaccine · doi:10.1016/j.vaccine.2017.05.070 · Cited by 59
Two-miRNA–based finger-stick assay for estimation of absorbed ionizing radiation dose
Yadav, M., Bhayana, S., Liu, J., Lu, L., Huang, J. B., Ma, Y., Qamri, Z., Mo, X. M., Jacob, D. S., Parasa, S. T., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aaw5831 · Cited by 59
Bankruptcy filing worries developers of nanoparticle cancer drugs
Ledford, H. K. (2016) · Nature · doi:10.1038/533304a · Cited by 58
MicroRNAs in Vascular Eye Diseases
Liu, C., Huang, S., Britton, W. R., & Chen, J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21020649 · Cited by 56
Nanobodies for Medical Imaging: About Ready for Prime Time?
Berland, L., Kim, L., Abousaway, O., Mines, A., Mishra, S., Clark, L. M., Hofman, P. M., & Rashidian, M. (2021) · Biomolecules · doi:10.3390/biom11050637 · Cited by 56
Neidhart, J. D., Allen, K. O., Barlow, D. L., Carpenter, M., Shaw, D. R., Triozzi, P. L., & Conry, R. M. (2003) · Vaccine · doi:10.1016/j.vaccine.2003.08.021 · Cited by 55
Chua, H. L., Plett, P. A., Sampson, C. H., Katz, B. P., Carnathan, G. W., MacVittie, T. J., Lenden, K., & Orschell, C. M. (2013) · Health Physics · doi:10.1097/hp.0b013e3182a4df10 · Cited by 55
Matijevic, M., Hedley, M. L., Urban, R. G., Chicz, R. M., Lajoie, C., & Luby, T. M. (2011) · Cellular Immunology · doi:10.1016/j.cellimm.2011.04.005 · Cited by 51
Preclinical Justification of pbi-shRNA EWS/FLI1 Lipoplex (LPX) Treatment for Ewing's Sarcoma
Rao, D. D., Jay, C. M., Wang, Z., Luo, X., Kumar, P., Eysenbach, H., Ghisoli, M. L., Senzer, N. N., & Nemunaitis, J. J. (2016) · Molecular Therapy · doi:10.1038/mt.2016.93 · Cited by 50
Waters, V. J., & Ratjen, F. A. (2014) · Expert Review of Respiratory Medicine · doi:10.1586/17476348.2014.918507 · Cited by 48
Antibody fragments: Prolonging circulation half-life special issue-antibody research
Herrington-Symes, A. P., Farys, M., Khalili, H., & Brocchini, S. (2013) · Advances in Bioscience and Biotechnology · doi:10.4236/abb.2013.45090 · Cited by 47
Oncolytic Viral Therapy for Mesothelioma
Pease, D. F., & Kratzke, R. A. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00179 · Cited by 47
Bender, C., Maese, L. D., Carter‐Febres, M., & Verma, A. R. (2021) · Blood and Lymphatic Cancer Targets and Therapy · doi:10.2147/blctt.s245210 · Cited by 47
Safety and Toxicological Considerations of Nanomedicines: The Future Directions
Patel, P., & Shah, J. (2017) · Current Clinical Pharmacology · doi:10.2174/1574884712666170509161252 · Cited by 44
Ishikawa, T., Kageyama, S., Miyahara, Y., Okayama, T., Kokura, S., Wang, L., Sato, E., Yagita∥, H., Itoh, Y., & Shiku, H. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-021-02892-w · Cited by 44
Shimoda, M., Tomimaru, Y., Charpentier, K. P., Safran, H. P., Carlson, R. I., & Wands, J. R. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.12.016 · Cited by 42
Yin, J., Cao, H., Wang, H., Sun, K., Li, Y., & Zhang, Z. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.06.004 · Cited by 42
Self-citationJimeno, A., Gupta, S., Sullivan, R., Do, K. T., Akerley, W. L., Wang, D., Teoh, D., Schalper, K., Zacharek, S. J., Sun, J., et al. (2020) · Cancer Research · doi:10.1158/1538-7445.am2020-ct032 · Cited by 41
Carignan, D., Herblot, S., Laliberté-Gagné, M.-È., Bolduc, M., Duval, M., Savard, P. E., & Leclerc, D. (2017) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2017.10.015 · Cited by 39
Tan, T., Wang, Y., Wang, J., Wang, Z., Wang, H., Cao, H., Li, J., Li, Y., Zhang, Z., & Wang, S. (2019) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2019.05.006 · Cited by 39
Self-citationNanomedicine: A Diagnostic and Therapeutic Approach to COVID-19
Sharma, A., Kontodimas, K., & Bosmann, M. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.648005 · Cited by 39
Recent advances in the bioanalytical methods of polyethylene glycols and PEGylated pharmaceuticals
Zhang, Z., Zhang, Y., Song, S., Yin, L., Sun, D. S., & Gu, J. (2020) · Journal of Separation Science · doi:10.1002/jssc.201901340 · Cited by 37
Self-citationCapromab Pendetide: A Review of its Use as an Imaging Agent in Prostate Cancer
Lamb, H. M., & Faulds, D. M. (1998) · Drugs & Aging · doi:10.2165/00002512-199812040-00004 · Cited by 36
Prolonged Release and Functionality of Interleukin-10 Encapsulated within PLA-PEG Nanoparticles
Duncan, S. A., Dixit, S., Sahu, R., Martin, D., Baganizi, D. R., Nyairo, E., Villinger, F. J., Singh, S. R., & Dennis, V. A. (2019) · Nanomaterials · doi:10.3390/nano9081074 · Cited by 36
Trends in Therapeutic Conjugates: Bench to Clinic
Rudra, A., Li, J., Shakur, R., Bhagchandani, S. H., & Langer, R. (2020) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.9b00828 · Cited by 36
Self-citationExploiting Oncogenic Drivers along the CCNG1 Pathway for Cancer Therapy and Gene Therapy
Al-Shihabi, A., Chawla, S. P., Hall, F. L., & Gordon, E. M. (2018) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2018.11.002 · Cited by 30
Wang, Y., Tan, X., Fan, X., Zhao, L., Wang, S., He, H., Yin, T., Zhang, Y. X., Tang, X., Jian, L., et al. (2021) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2021.1903428 · Cited by 28
Sofias, A. M., Combes, F., Koschmieder, S., Storm, G., & Lammers, T. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.02.017 · Cited by 27
Novel Experience in Hybrid Tracers
Manca, G., Garau, L. M., Mazzarri, S., Mazzuca, L., Muccioli, S., Ghilli, M., Naccarato, A. G., Colletti, P. M., Rubello, D., Roncella, M., et al. (2020) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000003478 · Cited by 25
Gabri, M. R., Mazorra, Z., Ripoll, G. V., Mesa, C., Fernandez, L. E., Gomez, D. E., & Alonso, D. F. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1075 · Cited by 23
Mertès, P., Collange, O., Coliat, P., Banerjee, M., Diringer, M., Roche, A., Delabranche, X., Chaban, V., Voegelin, M., Bernard, A., et al. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.06.033 · Cited by 21
Aguilar, F. F., Barranco, J. J., Bover, E., Aguilera, L. C., Sáez, Y. L., Santana, M. D. C., Vázquez, E. P., Baker, R. B., Acosta, O. R., Pérez, H. G., et al. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.08.020 · Cited by 20
Hnik, P., Wasan, E. K., & Wasan, K. M. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01450-20 · Cited by 20
Discontinued drugs in 2011: oncology drugs
Williams, R. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2013.739605 · Cited by 19
Johnson, M. L., El-Khoueiry, A. B., Hafez, N., Lakhani, N. J., Mamdani, H. M., Rodon, J. A., Sanborn, R. E., Ho, T., Li, R., Waldes, J., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.15_suppl.3502 · Cited by 18
Antibody drug conjugates: Development, characterization, and regulatory considerations
Kommineni, N., Pandi, P., Chella, N., Domb, A. J., & Khan, W. (2019) · Polymers for Advanced Technologies · doi:10.1002/pat.4789 · Cited by 17
Mutational and biophysical robustness in a prestabilized monobody
Chandler, P. G., Tan, L. L., Porebski, B. T., Green, J. S., Riley, B. T., Broendum, S. S., Hoke, D. E., Falconer, R. J., Munro, T. P., Buckle, M., et al. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.100447 · Cited by 11
The Current State of Topical Burn Treatments: a Review
Hashmi, D. L., & Haith, L. R. (2019) · Current Trauma Reports · doi:10.1007/s40719-019-00170-w · Cited by 9
A first step toward in vivo gene editing in patients
Büning, H., & Schambach, A. (2021) · Nature Medicine · doi:10.1038/s41591-021-01476-6 · Cited by 6
Cited by
Microfluidic Devices: A Tool for Nanoparticle Synthesis and Performance Evaluation
Gimondi, S., Ferreira, H., Reis, R. L., & Neves, N. M. (2023) · ACS Nano · doi:10.1021/acsnano.3c01117 · Cited by 376
A translational framework to DELIVER nanomedicines to the clinic
Joyce, P., Allen, C. J., Alonso, M. J., Ashford, M., Bradbury, M. S., Germain, M., Kavallaris, M., Langer, R., Lammers, T., Peracchia, M. T., et al. (2024) · Nature Nanotechnology · doi:10.1038/s41565-024-01754-7 · Cited by 333
Nanotechnology in healthcare, and its safety and environmental risks
Ma, X., Tian, Y., Yang, R., Wang, H., Allahou, L. W., Chang, J., Williams, G., Knowles, J. C., & Poma, A. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02901-x · Cited by 332
Clinical translation of nanomedicines for brain diseases: Current challenges and future directions
Wang, G., Wang, N., Xia, X., Ismail, M., & Shi, B. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114426 · Cited by 33
Metadata
- Authors
- Shan, X., Gong, X., Li, J., Wen, J., Li, Y., & Zhang, Z.
- Venue
- Acta Pharmaceutica Sinica B
- Publisher
- Elsevier BV
- Published
- 2022-07
- Volume
- 12
- Issue
- 7
- Pages
- 3028-3048
- ISSN
- 2211-3835 (ISSN-L)
- OpenAlex
- W4214767244
- Cited by
- 335
- References
- 176
- FWCI
- 15.05
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.